Antimicrobial resistance patterns of isolates from urine cultures at an oncological center;Patrones de resistencia bacteriana en urocultivos en un hospital oncológico

Salud Publica de Mexico

Volumn 49, Issue 5, 2007, Pages 330-336

  Cornejo Juárez, Patricia ^a   Velásquez Acosta, Consuelo ^a   Sandoval, Silvia ^a   Gordillo, Patricia ^a   Volkow Fernández, Patricia ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Antimicrobial; Bacterial drug resistance; Mexico; Nosocomial; Urine

Indexed keywords

EID: 36448946198     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342007000500003     Document Type: Article

References (24)

1. Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western pacific region: report form the SENTRY Antimicrobial Surveillance Program, 1998-1999. Int J Antimicrob Agents 2002;20:10-17.
2. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001;119(suppl 2):397S-404S.
3. World Health Organization-Antimicrobial resistance. Fact sheet No 194. Revised January 2002. [Consultado 19 agosto 2006]. Disponible en: www.who.int/mediacentre/factsheets/fs194/en/print.html.
4. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: a strategy priority for hospitals worldwide. Clin Infect Dis 1997;24(suppl 1):S139-S145.
5. Oplustil CP, Nunes R, Mendes C, RESISTNET Group. Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp and Shigella spp isolated from clinical specimens in Brazil. RESISTNET Surveillance Program. Braz J Infect Dis 2001;5:8-12.
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing for bacteria that grow aerobically. (Eleventh Informational Supplement). Wayne (PA): NCCLS; 2001. Document M100-S11.
7. Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn Microbiol Infect Dis 2001;41:161-3.
8. Valdivieso F, Trucco O, Prado V, Díaz MC, Ojeda A, Grupo PRONARES. Antimicrobial resistance of agents causing urinary tract infections in 11 Chilean hospitals. PRONARES project. Rev Med Chil 1999;127:1033-40.
9. Savas L, Guvel S, Orlen Y, Savas N, Duran N. Nosocomial urinary tract infections: micro-organisms, antibiotic sensitivies and risk factors. West Indian Med J 2006;55:188-193.
10. Vallano A, Rodríguez D, Barcelo ME, López A, Cano A, Vinado B, et al. Antimicrobial susceptibility of uropathogens and outcome following antibiotic treatment for urinary tract infections in primary healthcare. Enferm Infecc Microbiol Clin 2006;24:418-25.
11. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
12. Patterson JE. Hospital-acquired infections: realities of risk and resistance. Chest 2001;119(suppl 2):426S-430S.
13. Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JEJr. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project: National Nosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001;33:324-30.
14. Recommendations for preventing the spread of vancomycin resistance recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR 1995;44(RR12):1-13.
15. Sifuentes-Osornio J, Ponce de León A, Muñoz-Trejo T, Villalobos-Zapata Y, Ontiveros-Rodríguez C, Gómez-Roldán C. Antimicrobial susceptibility patterns and high-level gentamicin resistance among enterococci isolated in a Mexican tertiary care center. Rev Invest Clin 1996;48:91-6.
16. Calderón-Jaimes E, Arredondo-García JL, Aguilar-Ituarte F, García-Roca P. In vitro antimicrobial susceptibility in clinical isolates of Enterococcus species. Salud Publica Mex 2003;45:96-101.
17. Goldmann DA, Weinstein RA, Wenzel RP, Tublan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996;275:234-40.
18. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14 (suppl 1):S43-S53.
19. Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis 2001;32:1602-7.
20. Cornejo-Juárez P, Velásquez-Acosta C, Díaz- González A, Volkow-Fernández P. Tendencia del perfil de sensibilidad antimicrobiana de los aislamientos de sangre en un hospital oncológico (1998-2003). Salud Publica Mex 2005;47:288-293.
21. Raymond DP, Pelletier SJ, Cabtree TD, Gleason TG, Hamm LL, Pruett TL, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001;29:1101-1108.
22. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravinshankar J, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumanii and Pseudomonas aeruginosa in Brooklyn, NY. Arch Intern Med 2002;162:1515-1520.
23. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005;5:481-493.
24. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 2005;5:568-80.